Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 3 3Phase 1/2 3Phase 4 2Phase NA 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 140Lymphoid 43Other hematologic neoplasm 35Thoracic 6Genitourinary 6Gastrointestinal 6Myeloid 4CNS 4Tumor-Agnostic 3Gynecologic 3Breast 3Head & Neck 2Dermatologic 2Other solid neoplasm 1NET 1Endocrine 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Dexamethasone × Tumor-Agnostic × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
83 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01267084 2015-10-14

A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Janssen Research & Development, LLC

Phase 1/2 Completed
12 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡